clinical trial · NCT05028166

Individual Patient Compassionate Use of Mirdametinib

SpringWorks Therapeutics, Inc.·—·available

Neurofibromatosis Type 1-Associated Plexiform NeurofibromasHistiocytic NeoplasmOther MAP-K Pathway Driven DiseasesMirdametinib (MEK Inhibitor)

brief summary

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

started

—

primary completion

—

completion

—

last updated

Mar 27, 2026

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol